Non-bleeding side effects of clopidogrel: Have large multi-center clinical trials underestimated their incidence?

Zakaria A. Almsherqi, Craig S. McLachlan, Sadik M. Sharef

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Large multi-center clinical trials have indicated significant clinical benefits for patients with atherosclerotic vascular diseases receiving clopidogrel therapy. Clopidogrel efficacy has been proven in cardiac and extracardiac vascular diseases. Thus, the popularity of using clopidogrel is likely to increase in the near future. However, clopidogrel therapy may be accompanied by rare life-threatening adverse events. An increasing body of evidence show that clopidogrel is associated with aplastic anemia, thrombocytopenia and neutropenia. Interestingly, the majority of multi-center clinical trials have reported bleeding as the major side effect of clopidogrel therapy and failed to detect the actual incidence of other serious hematological side effects. Highlighting the potential adverse events of clopidogrel therapy in large clinical trials is therefore essential if we are to learn any lessons from having ignored the reporting of serious adverse side effects of a closely related drug (ticlopidine) in its large clinical trials.

Original languageEnglish
Pages (from-to)415-417
Number of pages3
JournalInternational Journal of Cardiology
Volume117
Issue number3
DOIs
Publication statusPublished - 2 May 2007
Externally publishedYes

    Fingerprint

Keywords

  • Clinical trials
  • Clopidogrel
  • Side effects
  • Ticlopidine

Cite this